Bristol-Myers Squibb Company vs Cloudflare, Inc.: Strategic Comparison

This in-depth comparison examines Bristol-Myers Squibb Company and Cloudflare, Inc. across revenue, market value, business model, competitive positioning, and long-term growth strategy. Whether you are researching Bristol-Myers Squibb Company on its own, evaluating Cloudflare, Inc., or weighing the two companies side by side, the breakdown below highlights where each company leads and where the gap between Bristol-Myers Squibb Company and Cloudflare, Inc. is widest.

On the headline numbers, Bristol-Myers Squibb Company reports annual revenue of $48.2B against $2.2B for Cloudflare, Inc., while their respective market capitalizations stand at $127.5B and $122.5B. Both Bristol-Myers Squibb Company and Cloudflare, Inc. are headquartered in United States, so they compete in a shared home market and regulatory environment.

Bristol-Myers Squibb Company: Bristol Myers Squibb (BMS) is a U.S. biopharmaceutical company headquartered in Princeton, New Jersey, and listed on the New York Stock Exchange as BMY. It develops and sells prescription medicines for cancer, blood disorders, immune diseases, heart disease and schizophrenia. Its best-known products are Eliquis, the anticoagulant it sells with Pfizer, and Opdivo, a PD-1 checkpoint inhibitor. With $48.2 billion of 2025 revenue and a market value of about $127 billion at the end of September 2026, it is one of the largest U.S. drugmakers by sales.

Cloudflare, Inc.: Cloudflare sits between internet users and the websites, apps, and corporate networks they connect to. When traffic passes through its network, Cloudflare caches content close to users, filters out attacks such as DDoS floods and malicious bots, and can run customer code at the edge. It says roughly 20% of websites use its services. Founded in 2009 and headquartered in San Francisco, the company went public on the NYSE in September 2019 and had 5,156 full-time employees at the end of 2025.

Bristol-Myers Squibb Company and Cloudflare, Inc. pursue distinct approaches to generating revenue, and understanding how each company operates is the foundation of any fair comparison between Bristol-Myers Squibb Company and Cloudflare, Inc..

Bristol-Myers Squibb Company business model: BMS discovers, licenses or buys drug candidates, takes them through clinical trials, and sells approved medicines under patent protection to wholesalers, specialty pharmacies and hospitals. Net product sales were $46.8 billion of the $48.2 billion total in 2025; alliance, royalty and other revenues made up the remaining $1.4 billion, including royalties from Merck on Winrevair. Eliquis is developed and sold with Pfizer, which shares its costs and profits. About 69 percent of 2025 revenue came from the United States, so U.S. pricing policy matters more to BMS than to most European rivals. Because every patent runs out, the model depends on replacing revenue: BMS paid $74 billion for Celgene in 2019, $13.1 billion for MyoKardia in 2020 and about $23 billion for Karuna, Mirati and RayzeBio in early 2024.

Cloudflare, Inc. business model: Cloudflare makes money by selling subscriptions and usage-based services that run on a single global network. Millions of websites use a free plan; paying customers move up to Pro, Business, and Enterprise plans for advanced DDoS mitigation, web application firewall, bot management, and support. Enterprises also buy Cloudflare One, a Zero Trust and SASE suite priced per user that replaces corporate VPNs, plus email security. A fast-growing developer platform (Workers, R2 storage, D1, Workers AI) bills on usage. Because every server runs the full software stack, new products ride on infrastructure Cloudflare already operates, which keeps non-GAAP gross margin in the mid-70s (75.8% in 2025).

The durability of a company's moat often decides long-term winners. Here is how the competitive advantages of Bristol-Myers Squibb Company stack up against those of Cloudflare, Inc..

Bristol-Myers Squibb Company competitive advantage: BMS's advantage is its expertise in oncology and its large commercial and regulatory organization. Developing a cancer immunotherapy is complex, and winning approval from regulators and getting doctors to prescribe it requires an established global sales and regulatory team. Smaller biotech companies often lack that infrastructure, so they partner with or sell to a company like BMS to bring their discoveries to market.

Cloudflare, Inc. competitive advantage: Cloudflare's advantage is its network: data centers in more than 330 cities that run every product on every server, combined with a free tier that brings an enormous volume of diverse traffic onto the platform. That traffic gives Cloudflare broad visibility into attacks, and the shared architecture lets it launch new security, AI, and developer products to its whole customer base at low marginal cost.

Future prospects matter as much as current results. The growth strategies below explain how Bristol-Myers Squibb Company and Cloudflare, Inc. each plan to expand from here.

Bristol-Myers Squibb Company growth strategy: BMS is pursuing growth on three fronts. First, scaling the Growth Portfolio (Opdivo Qvantig, Reblozyl, Camzyos, Breyanzi, Opdualag, Cobenfy and others), which rose 17 percent to $26.4 billion in 2025 and 15 percent to $7.56 billion in the second quarter of 2026. Second, buying and licensing late-stage science: Mirati ($4.8 billion plus a contingent value right of up to $1 billion), RayzeBio ($4.1 billion) and Karuna ($14 billion) closed in early 2024; a June 2025 deal with BioNTech for the bispecific BNT327 carried $1.5 billion upfront and up to $11.1 billion in total; and Orbital Therapeutics was bought for $1.5 billion in October 2025 for in vivo CAR-T in autoimmune disease. Third, cost cuts: a $1.5 billion savings program announced in 2024 was extended in 2025 with a further $2 billion targeted by the end of 2027.

Cloudflare, Inc. growth strategy: Cloudflare grows by landing customers with free or low-cost plans and expanding into more products per account. Its main growth vectors are larger enterprise contracts (it signed its largest-ever deal in Q4 2025, averaging $42.5 million per year in annual contract value), Cloudflare One Zero Trust, and the developer platform. In 2025-2026 it leaned into AI: Workers AI for inference, the Replicate model platform acquired in late 2025, AI crawler controls for publishers, and acquisitions of web framework teams (Astro, VoidZero/Vite) to pull more developers onto Workers.

A closer look at the financial trajectory of Bristol-Myers Squibb Company and Cloudflare, Inc. rounds out the comparison.

Bristol-Myers Squibb Company: Revenue grew from $19.4 billion in 2016 to $42.5 billion in 2020 as Celgene's sales were added, and has stayed between $45.0 billion and $48.3 billion since 2021. Net earnings are far less stable because BMS expenses acquired in-process R&D: the $11.4 billion MyoKardia charge produced a $9.0 billion net loss in 2020, and the Karuna charge produced an $8.9 billion loss in 2024. Cash generation is steadier, with free cash flow of about $12.8 billion in 2025. That cash funds a dividend raised for a 17th straight year in February 2026, to $0.63 a quarter, and debt reduction, from $51.2 billion at the end of 2024 to $47.2 billion a year later. On July 30, 2026 BMS raised its 2026 revenue guidance to $49.0 to $50.0 billion, from $46.0 to $47.5 billion, after second-quarter revenue rose 6 percent to $12.97 billion.

Cloudflare, Inc.: Cloudflare's revenue has compounded from $431.1 million in 2020 to $2.17 billion in 2025. In 2025 it posted 29.8% growth, 75.8% non-GAAP gross margin, $303.9 million of non-GAAP operating income (14.0% of revenue), $603.1 million of operating cash flow, and $260.6 million of free cash flow, while still reporting a $102.3 million GAAP net loss driven by stock-based compensation. Growth accelerated in 2026: Q2 2026 revenue was $696.1 million (+36% year over year), with a $170.0 million GAAP net loss and $107.8 million of non-GAAP net income. Cash and securities stood at $4.16 billion on June 30, 2026. Management raised full-year 2026 revenue guidance to $2.864-$2.870 billion in August 2026.